by David Wallace Understanding Thrombosis in MPN Patients Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers that affect the normal functioning of blood cells. People living with MPNs, such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), have an increased risk of developing blood clots, or thrombosis. Thrombosis can lead to […]
Dr. Srdan Verstovsek Joins Kartos Therapeutics as CMO
World-Renowned Physician-Scientist and Global Expert in Myeloproliferative Neoplasms Will Be Instrumental in Advancing the Development of Navtemadlin and Other Innovative Therapies to Improve the Lives of Cancer Patients REDWOOD CITY, Calif., March 02, 2023–(BUSINESS WIRE)–Kartos Therapeutics, Inc. (“Kartos” or the “Company”), a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that […]
Modified CALR Mutation helps Identify New Drug Targets for MPN Cancer
Summary The research article discusses myeloproliferative neoplasms (MPN), a type of cancer that affects the blood and bone marrow. It focuses on the Calreticulin (CALR) mutation found in 20% to 25% of MPN patients (with ET and MF) and, which is a potential target for new drug therapies. The authors describe a novel approach using […]
Blood Cancer Discovery: Scientists Create Human Bone Marrow Organoids to Improve Anti-Cancer Treatments
Summary This blood cancer discovery highlights a new approach for investigating blood cancers and bone marrow disorders. MPNs or myeloproliferative neoplasms are blood cancers in which the bone marrow makes too many red blood cells, platelets or white blood cells. Currently, there are limited models available to understand the development and response to treatments of […]
How important is fibrosis in myelofibrosis?
by David Wallace What is fibrosis in myelofibrosis? Myelofibrosis is characterized by an accumulation of fibrous tissue (fibrosis) or scar tissue in the bone marrow. As fibrosis increases, it impairs the bone marrow’s ability to produce healthy blood cells. This can cause numerous symptoms, including anemia, fatigue, weakness and an increased risk of bleeding and […]
Dr. Ruben Mesa named to Lead Atrium Health Cancer Program
Atrium Health recently announced Dr. Ruben A. Mesa has been named president and executive director of its cancer service line – which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center – and vice dean for cancer programs at Wake Forest University School of Medicine. Mesa will assume the roles filled by Dr. […]
Theories on Treatment of Polycythemia Vera with Interferon-β
Simple Summary The myeloproliferative neoplasms (MPNs) are chronic blood cancers characterized by elevated blood cell counts and, after decades, the development of bone marrow failure. Blood clots are common and contribute massively to the symptom burden. Treatment with interferon (IFN) alpha-2 normalizes elevated blood cell counts within weeks to months. This treatment has been used […]
Real-World Treatments and Thrombotic Events in U.S. based Polycythemia Vera Patients
Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive medications, are targeted to maintain hematocrit levels < 45% to prevent adverse outcomes. This retrospective observational study examined medical and pharmacy claims of 28,306 PV patients initiating treatment for PV in a data period […]
PharmaEssentia Announces New Research and Development Center in Boston
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation January 4, 2023 8:00 AM EST TAIPEI,Taiwan–(BUSINESS WIRE)–PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced […]
Is there a Connection between MPNs and Autoimmune Diseases?
by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to autoimmune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 20
- Next Page »